Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of…

By Silvio E. Inzucchi, R. Bergenstal, John B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. Peters, A. Tsapas, R. Wender, D. Matthews. Diabetes Care, 2014

2,951 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0727c4cf3718673d1326a4efe44838cb9272ed39

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Molecular Biology

Citations in the corpus

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials (2017, background): “Glucose control is a central focus in the management of T2DM [2], and reducing hyperglycemia has been shown to decrease microvascular complications of diabetes [3, 4].”
Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes (2016, background): “Type 2 Diabetes A patient-centered approach should guide the choice of pharmacologic agents (18).”
Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes – Mechanisms, Management, and Clinical Considerations (2016, positive): “Patients on statins at higher risk for but without preexisting type 2 diabetes mellitus should undergo periodic screening for diabetes mellitus with fasting glucose and HbA 1c , and if type 2 diabetes mellitus develops, standard of care and national guidelines should be used to manage diabetes melli”
6. Glycemic Targets: Standards of Medical Care in Diabetes—2019 (2018, background): “but to be used as a broad construct to guide clinical decision making (40) in both type 1 and type 2 diabetes.”
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis (2016, background): “Though therapeutic algorithms for diabetes encourage individualization of approaches (1), they are often broadly applied in treatment and reimbursement decisions, reinforcing the “one-size-fits-all” approach (2).”
6. Glycemic Targets: Standards of Medical Care in Diabetes—2020 (2019, neutral): “guide clinical decision-making (47) and”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, positive): “cases lipids, should be less stringently implemented in older people with DM, those with a longer duration of DM, those with evidence of CVD and the frail [401].”